text
Disclosures for H.C. Wainwright & Co., LLC, Spectrum Pharmaceuticals, Inc. (SPPI), March 18, 2022
I, Edward White , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all
subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the
specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household
is an officer, director or advisory board member of these companies.
None of the research analysts or the research analyst’s household has a financial interest in the securities of Spectrum
Pharmaceuticals, Inc. (including, without limitation, any option, right, warrant, future, long or short position).
As of February 28, 2022 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities
of Spectrum Pharmaceuticals, Inc..
Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time
of publication of this research report.
The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any
specific investment banking services or transaction but is compensated based on factors including total revenue and profitability
of the Firm, a substantial portion of which is derived from investment banking services.
The firm or its affiliates received compensation from Spectrum Pharmaceuticals, Inc. for non-investment banking services in
the previous 12 months.
The Firm or its affiliates did receive compensation from Spectrum Pharmaceuticals, Inc. for investment banking services within
twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services
within three months following publication of the research report.
H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Spectrum Pharmaceuticals, Inc. during
the past 12 months.
The Firm does not make a market in Spectrum Pharmaceuticals, Inc. as of the date of this research report.
